[221 Pages Report] Revenue from the global cytomegalovirus treatment market currently stands at US$ 228.8 Million in 2022. Rising at a CAGR of 6.1% (2022 to 2028), demand for cytomegalovirus treatment is predicted to reach a market valuation of US$ 326 Million by the end of 2028.
| Attribute | Details |
|---|---|
| Global Cytomegalovirus Treatment Market Size (2022) | US$ 228.8 Million |
| Net Revenue Estimation (2028) | US$ 326 Million |
| Global Growth Rate (2022 to 2028) | 6.1% CAGR |
| Market Share of Hospital Pharmacies | 47.8% |
Cytomegalovirus treatment contributes 0.8% to the global infectious disease diagnostics market revenue. Increasing instances of viral infections and rising awareness of cytomegalovirus symptoms are expected to propel demand for cytomegalovirus treatment on a global level.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
| Particulars | Details |
|---|---|
| H1, 2021 | 6.10% |
| H1, 2022 Projected | 6.08% |
| H1, 2022 Outlook | 5.48% |
| BPS Change - H1, 2022 (O) - H1, 2022 (P) | (-) 60 ↓ |
| BPS Change - H1, 2022 (O) - H1, 2021 | (-) 62 ↓ |
The comparative analysis and market growth rate of global cytomegalovirus treatment market as studied by Future Market Insights, will show a negative BPS growth in H1-2022 outlook as compared to H1-2022 projected period by 60 BPS. A decline in BPS growth is expected in H1-2022 over H1- 2021 duration with 62 Basis Point Share (BPS).
The market for cytomegalovirus treatment is subject to changes as per the macro and industrial standards in relevance to stringent regulations in biopharmaceuticals development and production and licensing.
The market observes a decline in the BPS values owed to the inefficacy of the therapy in patients with severe immunosuppression or disseminated disease. With the rising cases of such incidences after the global coronavirus pandemic, the limitations for cytomegalovirus treatment posed a negative impact upon the market growth, thus resulting in the dropped BPS values.
Conversely, with the recent FDA approval of the first drug for adults and paediatric patients with cytomegalovirus infections and diseases which cannot be managed with the current available antiviral treatment methods in 2022, has paved way for the market to observe a positive outlook towards growth over the forecasted years.
The key development in the market includes the adoption of oral antivirals such as ganciclovir for the management of cytomegalovirus in immunocompromised patients.
The world has seen substantial rise in viral infections and other infectious diseases, and this has propelled demand for better diagnostic and treatment solutions. The cytomegalovirus treatment market exhibited expansion at a CAGR of 5.7% from 2013 to 2021.
Increasing prevalence of congenital CMV infections, rising awareness about cytomegalovirus symptoms, increasing spending on research & development activities, rising clinical trials and studies for CMV infections, etc., are major trends that will guide cytomegalovirus treatment demand through 2028.
The risk of reactivation of cytomegalovirus infections in multiple individuals has been observed and this is one of the areas of prime focus for many cytomegalovirus treatment providers. The use of antiviral agents that have very low risks associated with them is seeing high demand in the development of antiviral drugs for cytomegalovirus diseases. Antiviral agents such as ganciclovir and valganciclovir are expected to see a rise in popularity over the forecast period.
Risks and side effects associated with antiviral drugs for cytomegalovirus diseases are anticipated to restrain market potential to a certain extent over the forecast period. The cytomegalovirus treatment industry is projected to rise at a steady CAGR of 6.1% from 2022 to 2028.
“Increasing Focus on Development of CMV Vaccines”
Awareness of cytomegalovirus symptoms is being raised across the world by multiple initiatives taken by governments and non-profit organizations to bolster public safety. Clinical trials are being carried out to boost the development of novel cytomegalovirus treatment.
“Risks of Antiviral Drugs for Cytomegalovirus Diseases Could Adversely Impact Market Growth”
Very little is known about CMV infections, and this has proven to be a major obstacle to cytomegalovirus diagnosis and cytomegalovirus testing. Increasing demand for cytomegalovirus natural treatment is also expected to constrain the adoption of antiviral drugs for cytomegalovirus diseases.
These factors are expected to have a hindering effect on global cytomegalovirus treatment device demand through 2028.
Principal Consultant
“High R&D Activity in North America to Boost Cytomegalovirus Diagnosis”
Detailed assessment of market stance across regions such as North America, Latin America, Europe, East Asia, South Asia & Pacific, and the Middle East & Africa (MEA) has been profiled in this revised FMI market analysis.
Demand for cytomegalovirus treatment products in North America is anticipated to hold a major market share in the global marketplace over the forecast. The presence of major cytomegalovirus treatment providers and rapid advancements in cytomegalovirus diagnosis and cytomegalovirus treatment are expected to shape market potential.
Rising prevalence of congenital CMV infections, increasing use of combinational antiviral therapies, and increasing awareness of cytomegalovirus treatment in stem cell transplants are expected to be major trends in the Europe cytomegalovirus treatment market over the forecast period.
Increasing investments in research & development activities, rising healthcare expenditure, and increasing popularity of cytomegalovirus natural treatment are major factors that influence cytomegalovirus treatment demand in South Asia and East Asia. Rising focus on boosting cytomegalovirus testing in these regions is expected to majorly favour market potential.
“Increasing Focus on Healthcare & Rising Awareness about Cytomegalovirus Symptoms in India”
The healthcare infrastructure in India is rapidly changing and the focus on health and hygiene has fostered a new wave of demand for better diagnostic and treatment solutions in the nation. Government initiatives are boosting awareness about viral infections and are further bolstering awareness about cytomegalovirus symptoms in India.
High population, increasing prevalence of HIV infections, high birthrate, etc., are some of the major factors that influence cytomegalovirus treatment market potential in India. Cytomegalovirus diagnosis and cytomegalovirus testing are expected to increase in India as awareness about cytomegalovirus symptoms increases through 2028.
“High Research Activity to Explore Cytomegalovirus Pathology to Boost Market Potential”
The U.S. is known for its well-established healthcare infrastructure, and this has made it a highly lucrative market for the healthcare industry. Cytomegalovirus treatment providers are expected to further advance their research & development activities to provide better cytomegalovirus diagnosis and treatment.
Rising research for cytomegalovirus testing, increasing investments from government and non-profit research organizations, and rising availability of cytomegalovirus diagnosis procedures are expected to be major factors influencing cytomegalovirus treatment market potential through 2028.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
“Hospital Pharmacies to Hold Dominant Market Share”
In 2022, hospital pharmacies account for 46.8% of the global cytomegalovirus treatment industry landscape. With most cytomegalovirus diagnosis procedures being accessible only through professional subscriptions, this has boosted their sales via hospital pharmacies, which are more accessible to patients and are recommended by professionals.
Other distribution channels such as retail pharmacies and e-Commerce currently hold market shares of 36.7% and 16.4%, respectively, in 2022, in the global cytomegalovirus treatment space.
In 2020, the healthcare industry was revolutionized by the emergence of coronavirus infections and adversely affected multiple treatment and diagnostic procedures across the world. As lockdown restrictions were imposed and outdoor activity was largely restricted, this led to a substantial drop in the research and development activities related to cytomegalovirus treatment.
Demand for cytomegalovirus treatment also experienced a drop during the pandemic era as all healthcare resources and professionals were focused on the treatment of coronavirus infections. However, the cytomegalovirus treatment market is predicted to make a steady comeback in the post-pandemic era as infections subside and the world returns to a new normal.
Cytomegalovirus treatment providers are investing in the research & development of innovative and more effective treatments for CMV infections.
| Attribute | Details |
|---|---|
| Forecast Period | 2022 to 2028 |
| Historical Data Available for | 2013 to 2021 |
| Market Analysis | US$ Mn for Value |
| Key Regions Covered |
|
| Key Countries Covered |
|
| Key Market Segments Covered |
|
| Key Companies Profiled |
|
| Pricing | Available upon Request |
Cytomegalovirus Treatment Market by Drug Type:
Cytomegalovirus Treatment Market by Application:
Cytomegalovirus Treatment Market by Distribution Channel:
Cytomegalovirus Treatment Market by Region:
Demand for cytomegalovirus treatment is predicted to increase at a CAGR of 6.1% from 2022 to 2028.
The global cytomegalovirus treatment market stands at a net worth US$ 228.8 Mn in 2022.
By 2028, the global cytomegalovirus treatment market is anticipated to attain a valuation of US$ 326 Mn.
Prime market players such as Chimerix Inc., Thermo Fisher Scientific, Abbot, Becton Dickinson and Company, Pfizer Inc., Merck & Company Inc., Mylan N.V., Johnson & Johnson, and Bio-Rad Laboratories Inc. have been profiled in this market survey.
At present, hospital pharmacies account for a dominant share of 46.8% in the global cytomegalovirus treatment industry.
1. Executive Summary 1.1. Market Overview 1.2. Market Analysis 1.3. FMI Analysis and Recommendations 1.4. Wheel of Fortune 2. Market Introduction 2.1. Market Taxonomy 2.2. Market Definition 3. Market Background 3.1. Market Overview 3.2. Macroeconomic Assumptions 3.3. Global Economic Outlook 4. Market Dynamics 4.1. Market Dynamics 4.1.1. Drivers 4.1.2. Restraints 4.1.3. Opportunity Analysis 4.1.4. Trends 5. Cytomegalovirus Treatment Market: Key Inclusions 5.1. Pipeline Analysis 5.2. Reimbursement Scenarios 5.3. Cytomegalovirus Treatment: Timeline 6. North America Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028 6.1. Introduction 6.2. Historical Market Size (US$ Mn) Analysis By Country, 2013–2021 6.2.1. U.S. 6.2.2. Canada 6.3. Market Size (US$ Mn) Opportunity Assessment By Country, 2022–2028 6.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2021 6.4.1. Ganciclovir 6.4.2. Valganciclovir 6.4.3. Foscarnet 6.4.4. Cidofovir 6.4.5. Others 6.5. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028 6.6. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021 6.6.1. Stem Cell Transplantation 6.6.2. Organ Transplantation 6.6.3. Congenital CMV infection 6.6.4. Others 6.7. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028 6.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 6.8.1. Hospital pharmacies 6.8.2. Retail Pharmacies 6.8.3. E-commerce 6.9. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028 6.10. Market Attractiveness Analysis 6.10.1. By Country 6.10.2. By Drug Type 6.10.3. By Application 6.10.4. By Distribution Channel 6.11. Drivers and Restraints – Impact Analysis 7. Western Europe Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028 7.1. Introduction 7.2. Historical Market Size (US$ Mn) By Country, 2013–2021 7.2.1. Germany 7.2.2. France 7.2.3. U.K. 7.2.4. Spain 7.2.5. Italy 7.2.6. Rest of Western Europe 7.3. Market Size (US$ Mn) Opportunity Assessment By Country, 2022–2028 7.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2021 7.4.1. Ganciclovir 7.4.2. Valganciclovir 7.4.3. Foscarnet 7.4.4. Cidofovir 7.4.5. Others 7.5. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028 7.6. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021 7.6.1. Stem Cell Transplantation 7.6.2. Organ Transplantation 7.6.3. Congenital CMV infection 7.6.4. Others 7.7. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028 7.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 7.8.1. Hospital pharmacies 7.8.2. Retail Pharmacies 7.8.3. E-commerce 7.9. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028 7.10. Market Attractiveness Analysis 7.10.1. By Country 7.10.2. By Drug Type 7.10.3. By Application 7.10.4. By Distribution Channel 7.11. Drivers and Restraints – Impact Analysis 8. Eastern Europe Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028 8.1. Introduction 8.2. Historical Market Size (US$ Mn) By Country, 2013–2021 8.2.1. Russia 8.2.2. Poland 8.2.3. Rest of Eastern Europe 8.3. Market Size (US$ Mn) Opportunity Assessment By Country, 2022–2028 8.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2021 8.4.1. Ganciclovir 8.4.2. Valganciclovir 8.4.3. Foscarnet 8.4.4. Cidofovir 8.4.5. Others 8.5. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028 8.6. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021 8.6.1. Stem Cell Transplantation 8.6.2. Organ Transplantation 8.6.3. Congenital CMV infection 8.6.4. Others 8.7. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028 8.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 8.8.1. Hospital pharmacies 8.8.2. Retail Pharmacies 8.8.3. E-commerce 8.9. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028 8.10. Market Attractiveness Analysis 8.10.1. By Country 8.10.2. By Drug Type 8.10.3. By Application 8.10.4. By Distribution Channel 8.11. Drivers and Restraints – Impact Analysis 9. Latin America Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028 9.1. Introduction 9.2. Historical Market Size (US$ Mn) By Country, 2013–2021 9.2.1. Brazil 9.2.2. Mexico 9.2.3. Rest of Latin America 9.3. Market Size (US$ Mn) Opportunity Assessment By Country, 2022–2028 9.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2021 9.4.1. Ganciclovir 9.4.2. Valganciclovir 9.4.3. Foscarnet 9.4.4. Cidofovir 9.4.5. Others 9.5. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028 9.6. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021 9.6.1. Stem Cell Transplantation 9.6.2. Organ Transplantation 9.6.3. Congenital CMV infection 9.6.4. Others 9.7. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028 9.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 9.8.1. Hospital pharmacies 9.8.2. Retail Pharmacies 9.8.3. E-commerce 9.9. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028 9.10. Market Attractiveness Analysis 9.10.1. By Country 9.10.2. By Drug Type 9.10.3. By Application 9.10.4. By Distribution Channel 9.11. Drivers and Restraints – Impact Analysis 10. Asia Pacific excluding China (APEC) Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028 10.1. Introduction 10.2. Historical Market Size (US$ Mn) By Country, 2013–2021 10.2.1. India 10.2.2. Australia and New Zealand 10.2.3. Japan 10.2.4. Rest of APEJ 10.3. Market Size (US$ Mn) Opportunity Assessment By Country, 2022–2028 10.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2021 10.4.1. Ganciclovir 10.4.2. Valganciclovir 10.4.3. Foscarnet 10.4.4. Cidofovir 10.4.5. Others 10.5. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028 10.6. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021 10.6.1. Stem Cell Transplantation 10.6.2. Organ Transplantation 10.6.3. Congenital CMV infection 10.6.4. Others 10.7. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028 10.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 10.8.1. Hospital pharmacies 10.8.2. Retail Pharmacies 10.8.3. E-commerce 10.9. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028 10.10. Market Attractiveness Analysis 10.10.1. By Country 10.10.2. By Drug Type 10.10.3. By Application 10.10.4. By Distribution Channel 10.11. Drivers and Restraints – Impact Analysis 11. China Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028 11.1. Introduction 11.2. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2021 11.2.1. Ganciclovir 11.2.2. Valganciclovir 11.2.3. Foscarnet 11.2.4. Cidofovir 11.2.5. Others 11.3. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028 11.4. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021 11.4.1. Stem Cell Transplantation 11.4.2. Organ Transplantation 11.4.3. Congenital CMV infection 11.4.4. Others 11.5. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028 11.6. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 11.6.1. Hospital pharmacies 11.6.2. Retail Pharmacies 11.6.3. E-commerce 11.7. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028 11.8. Market Attractiveness Analysis 11.8.1. By Drug Type 11.8.2. By Application 11.8.3. By Distribution Channel 11.9. Drivers and Restraints – Impact Analysis 12. MEA Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028 12.1. Introduction 12.2. Historical Market Size (US$ Mn) By Country, 2013–2021 12.2.1. GCC Countries 12.2.2. South Africa 12.2.3. Rest of MEA 12.3. Market Size (US$ Mn) Opportunity Assessment By Country, 2022–2028 12.4. Historical Market Size (US$ Mn) Trend Analysis By Drug Type, 2013–2021 12.4.1. Ganciclovir 12.4.2. Valganciclovir 12.4.3. Foscarnet 12.4.4. Cidofovir 12.4.5. Others 12.5. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028 12.6. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021 12.6.1. Stem Cell Transplantation 12.6.2. Organ Transplantation 12.6.3. Congenital CMV infection 12.6.4. Others 12.7. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028 12.8. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 12.8.1. Hospital pharmacies 12.8.2. Retail Pharmacies 12.8.3. E-commerce 12.9. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028 12.10. Market Attractiveness Analysis 12.10.1. By Country 12.10.2. By Drug Type 12.10.3. By Application 12.10.4. By Distribution Channel 12.11. Drivers and Restraints – Impact Analysis 13. Forecast Factors: Relevance and Impact 14. Competition Analysis 14.1. Competition Dashboard 14.2. Company Deep Dive 14.2.1. Merck & Co. Inc., 14.2.1.1. Overview 14.2.1.2. Product and Application Portfolio 14.2.1.3. Analyst Commentary 14.2.1.4. Strategy 14.2.1.4.1. Marketing Strategy 14.2.1.4.2. Product Strategy 14.2.1.4.3. Channel Strategy 14.2.2. Mylan N.V. 14.2.3. Chimerix, Inc., 14.2.4. Thermo Fisher Scientific 14.2.5. Abbott 14.2.6. Becton, Dickinson and Company, 14.2.7. Johnson & Johnson, 14.2.8. Bio-Rad Laboratories, Inc., 14.2.9. F. Hoffmann-La Roche Ltd 14.2.10. Pfizer 15. Global Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028, By Region 15.1. Introduction / Key Findings 15.2. Historical Market Size (US$ Mn) Trend Analysis By Region, 2013–2021 15.2.1. North America 15.2.2. Western Europe 15.2.3. Eastern Europe 15.2.4. Latin America 15.2.5. Asia Pacific excluding China 15.2.6. China 15.2.7. Middle East and Africa 15.3. Market Size (US$ Mn) Opportunity Assessment By Region, 2022–2028 15.4. Market Attractiveness Analysis By Region 16. Global Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028, By Drug Type 16.1. Introduction 16.2. Historical Market Size (US$ Mn) and Trend Analysis By Drug Type, 2013–2021 16.2.1. Ganciclovir 16.2.2. Valganciclovir 16.2.3. Foscarnet 16.2.4. Cidofovir 16.2.5. Others 16.3. Market Size (US$ Mn) Opportunity Assessment By Drug Type, 2022–2028 16.4. Market Attractiveness Analysis By Drug Type 17. Global Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028, By Application 17.1. Introduction 17.2. Historical Market Size (US$ Mn) Trend Analysis By Application, 2013–2021 17.2.1. Stem Cell Transplantation 17.2.2. Organ Transplantation 17.2.3. Congenital CMV infection 17.2.4. Others 17.3. Market Size (US$ Mn) Opportunity Assessment By Application, 2022–2028 17.4. Market Attractiveness Analysis By Application 18. Global Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028, By Distribution Channel 18.1. Introduction 18.2. Historical Market Size (US$ Mn) Trend Analysis By Distribution Channel, 2013–2021 18.2.1. Hospital pharmacies 18.2.2. Retail Pharmacies 18.2.3. E-commerce 18.3. Market Size (US$ Mn) Opportunity Assessment By Distribution Channel, 2022–2028 18.4. Market Attractiveness Analysis By Distribution Channel 19. Global Cytomegalovirus Treatment Market Analysis 2013–2021 and Opportunity Assessment 2022–2028 19.1. Market Value Share Analysis 19.1.1. By Country 19.1.2. By Drug Type 19.1.3. By Application 19.1.4. By Distribution Channel 19.2. Y-o-Y Growth Analysis 19.2.1. By Country 19.2.2. By Drug Type 19.2.3. By Application 19.2.4. By Distribution Channel 19.3. Absolute $ Opportunity 20. Assumptions and Acronyms Used 21. Research Methodology
Explore Healthcare Insights
View Reports
Cytomegalovirus Treatment Market
